The m6A methyltransferase METTL3 promotes LPS-induced microglia inflammation through TRAF6/NF-κB pathway

Area of Science:

• Neuroscience
• Immunology
• Molecular Biology

Background:

• Microglia are key players in central nervous system inflammation.
• Overactivated microglia release pro-inflammatory cytokines, contributing to neurodegeneration.
• Understanding the regulatory mechanisms of microglial activation is crucial for developing therapeutic strategies.

Purpose of the Study:

• To investigate the role of the m6A methyltransferase METTL3 in microglial inflammatory responses.
• To elucidate the molecular mechanism by which METTL3 influences microglial activation.
• To explore METTL3 as a potential target for inhibiting microglial overactivation.

Main Methods:

• Lipopolysaccharide (LPS) was used to induce microglial inflammation in vitro.
• Gene and protein expression levels of METTL3, inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-18), and signaling proteins (TRAF6, NF-κB, I-κB) were analyzed using RT-PCR, ELISA, and Western blot.
• m6A levels were assessed via dot blot and methylated RNA immunoprecipitation.
• Protein-protein interactions were confirmed using co-immunoprecipitation.

Main Results:

• LPS stimulation upregulated METTL3 expression and inflammatory mediators in microglia.
• METTL3 expression positively correlated with TRAF6, and they were found to interact.
• METTL3 promoted the activation of the TRAF6-NF-κB signaling pathway in an m6A-dependent manner.
• Inhibition of NF-κB activation attenuated METTL3-induced microglial activation.

Conclusions:

• METTL3 plays a significant role in promoting LPS-induced microglial inflammation.
• The mechanism involves METTL3-mediated activation of the TRAF6-NF-κB pathway.
• Targeting METTL3 or the TRAF6-NF-κB pathway may offer therapeutic potential for neuroinflammatory conditions.